Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan maintenance versus active observation with optional bevacizumab in newly diagnosed HRD-negative advanced ovarian cancer
jRCT2051260200Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Mocertatug rezetecan +/- Bevacizumab with Active Observation +/- Bevacizumab (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2051260200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260200.